Blend of PARP Inhibitors Shows Promising Activity against Small Cell Lung Cancer
Release Date: 20-Sep-2019
A combination of olaparib and temozolomide appeared safe and active in patient with relapsed small cell lung cancer (SLSC). Both the drugs belong to the class of Poly (ADP-ribose) polymerase (PARP) inhibitor. This result comes from the single-arm phase 1/2 trial. The findings were published online August 15, 2019, in Cancer Discovery.
The trial included a phase 1 dose-enhancement portion followed by a dose-expansion protocol during phase 2. The clinical trial consist of about a total of 50 patients with previously treated SCLC were enrolled across the 2 phases of the trial. Patients received a median of 2 lines of prior therapy (range, 1andndash;7), and the majority of patients (72%) had platinum-sensitive disease.
Four dose levels were evaluated during phase 1 of clinical trial. There is no treatment related events, dose limiting toxicities were observed at any of the dose levels. The recommended phase 2 dose (RP2D) ultimately selected was dose level 3, which was olaparib 200 mg orally twice daily and temozolomide 75 mg/mg daily.
From the total of 48 patients under the observation and analysis, 20 (41.7%) achieved a response, all of which were partial responses. Among the 39 patients who received the RP2D, the overall response rate was 41.0%, median progression-free survival was 4.2 months (95% CI, 2.5-5.7), and median overall survival was 6.7 months (95% CI, 4.6-12.6).
According to the lead study author Anna Farago, this combination showed significant clinical activity in patients with relapsed small cell lung cancer, and warrants investigation in a randomized study comparing olaparib plus temozolomide with the standard-of-care option.
Need custom market research solution? We can help you with that too.
Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and
service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers
understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas.